A survey of 321 seniors 65 and older revealed that 61% think the healthcare reform bill has weakened Medicare in the year since it became law.
A survey of 321 seniors 65 and older revealed that 61% think the healthcare reform bill has weakened Medicare in the year since it became law. At the same time, 57% of those surveyed say they will take advantage of a free physical exam and personal wellness plan benefit included in the bill that went into effect this year.
Moreover, 73% of seniors surveyed think the health care bill will continue to weaken Medicare over the long term. When asked about attempts under way in the U.S. House of Representatives to defund the bill, 43% of seniors surveyed support defunding the bill entirely and 29% think only certain provisions of the bill should be defunded.
The survey was fielded from March 18-21, 2011 by Extend Health, Inc., which operates a private Medicare exchange. The company says the bill does not cut any Medicare benefits, and instead adds some benefits, including the previously mentioned free physical exam and other free preventative care services.
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Phase 3 Trial of Vertex’s Islet Cell Therapy for Type 1 Diabetes Under Way
April 23rd 2025Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if approved, would be the second cell therapy for type 1 diabetes.
Read More